After just 13 biopharmaceutical companies went public in the US during the first four months of 2019, setting a pace of about three per month, five drug developers launched initial public offerings on 7 and 8 May – with mixed results.
Finance Watch: Five IPOs Launch In Two Days; Three Remain In Positive Territory
Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.
